|
|
News Breaks | | | | January 31, 2013 | | 06:25 EDT |  | TEVA | Teva terminates agreements with CureTech
Teva Pharmaceutical announced the termination of its collaboration with CureTech. "We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have made the strategic decision to invest our resources elsewhere where we can have the most impact for patients," stated Dr. Michael Hayden, president and CEO of R&D and Chief R&D Officer. | |
|
News For TEVA From The Last 14 Days Check below for free stories on TEVA the last two weeks. |
|
|
| May 22, 2013 | | 16:23 EDT | | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
 Subscribe for More Information | | | May 20, 2013 | | 11:27 EDT | | TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information | | | May 13, 2013 | | 09:44 EDT |  | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information | | | 07:49 EDT |  | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. | |
|
|
|
|
|
|
